Bayer HealthCare to sell Nuvelo's blood clotting agent; ends
Nuvelo (develops cardiovascular and cancer candidates) licensed Bayer HealthCare exclusive rights to market its Phase III thrombolytic alfimeprase outside of the US. Nuvelo retains exclusive US development and commercialization rights.
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.